Icosavax Inc

NASDAQ ICVX

Download Data

Icosavax Inc EBIT to Total Assets Ratio 1 year YoY Change (%) for the quarter ending September 30, 2023: -9.19%

Icosavax Inc EBIT to Total Assets Ratio 1 year YoY Change (%) is -9.19% for the quarter ending September 30, 2023, a -153.90% change year over year. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Icosavax Inc EBIT to Total Assets Ratio for the quarter ending September 30, 2022 was -0.09, a 17.05% change year over year.
  • Icosavax Inc EBIT to Total Assets Ratio for the quarter ending September 30, 2021 was -0.11.
NASDAQ: ICVX

Icosavax Inc

CEO Mr. Adam K. Simpson
IPO Date July 29, 2021
Location United States
Headquarters 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees 60
Sector Healthcare
Industry Biotechnology
Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email